专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06602687B1 DNA encoding human ciliary neurotrophic factor and method for producing the protein encoded thereby 失效
标题翻译：编码人睫状神经营养因子的DNA及其制备方法
公开(公告)号：US06602687B1
公开(公告)日：2003-08-05
申请号：US07883630
申请日：1992-05-08
申请人： Michael Sendtner , Kurt Stockli-Rippstein , Friedrich Lottspeich , Yoshihiro Arakawa , Patrick Desmond Carroll , Rudolf Georg Gotz , Georg W. Kreutzberg , Dan B. Lindholm , Piotr Masiakowski , Vivien Wong , Nancy Ip , Mark E. Furth , Nikos Panayotatos , Hans Thoenen
发明人： Michael Sendtner , Kurt Stockli-Rippstein , Friedrich Lottspeich , Yoshihiro Arakawa , Patrick Desmond Carroll , Rudolf Georg Gotz , Georg W. Kreutzberg , Dan B. Lindholm , Piotr Masiakowski , Vivien Wong , Nancy Ip , Mark E. Furth , Nikos Panayotatos , Hans Thoenen
IPC分类号： C12N1516
CPC分类号： C07K16/22 , A61K38/1825 , A61K38/185 , C07K14/475 , A61K38/18 , A61K31/715 , A61K2300/00
摘要： The present invention relates to nucleic acid sequences encoding ciliary neurotrophic factor (CNTF) and to the proteins, peptides, and derivatives produced therefrom. In various embodiments of the invention, the nucleic acid sequences, proteins, and peptides of the invention may be used in the treatment of a variety of neurological diseases and disorders, including Alzheimer's disease. In a specific embodiment of the invention, CNTF may be used to support the growth of spinal cord neurons, thereby providing a method of treating spinal cord damage caused by trauma infarction, infection, nutritional deficiency or toxic agents. The present invention also relates to a novel method for producing substantilly pure CNTF. The invention also relates to pharmaceutical compositions comprising effective amounts of CNTF gene products which may be used in the diagnosis and treatment of a variety of neurologial diseases and disorders. The present invention relates to the cloning sequencing and expression of CNTF and provides, for the first time, a means for producing human CNTF utilizing human CNTF-encoding nucleic acid sequences. Furthermore, the CNTF nucleic acid sequences of the invention may be utilized to identify nucleic acid sequences encoding CNTF or CNTF-homologous molecules in a variety of species and tissues.
摘要翻译：本发明涉及编码睫状神经营养因子（CNTF）的核酸序列以及由其产生的蛋白质，肽和衍生物。在本发明的各种实施方案中，本发明的核酸序列，蛋白质和肽可用于治疗各种神经疾病和病症，包括阿尔茨海默氏病。在本发明的一个具体实施方案中，CNTF可用于支持脊髓神经元的生长，从而提供治疗由创伤性梗塞，感染，营养缺乏或毒性剂引起的脊髓损伤的方法。本发明还涉及本发明还涉及包含有效量的可用于诊断和治疗多种神经系统疾病和病症的CNTF基因产物的药物组合物。本发明涉及克隆测序和表达的CNTF，并且首次提供了利用人CNTF编码核酸序列生产人CNTF的方法。此外，本发明的CNTF核酸序列可用于鉴定在各种物种和组织中编码CNTF或CNTF同源分子的核酸序列。

2. 发明授权

US5846935A Modified ciliary neurotrophic factors 失效
公开(公告)号：US5846935A
公开(公告)日：1998-12-08
申请号：US308736
申请日：1994-09-19
申请人： Nikos Panayotatos
发明人： Nikos Panayotatos
IPC分类号： A61K38/00 , A61P21/00 , A61P25/00 , A61P25/28 , B01D57/02 , C07K14/47 , C07K14/475 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/18 , C12P21/02 , C12R1/19 , G01N27/447 , G01N33/68 , A61K38/18 , C07K14/48
CPC分类号： G01N33/68 , C07K14/475 , Y10S930/12
摘要： Modified ciliary neurotrophic factors and methods for their production and therapeutic use. Also described is a method of screening for novel therapeutic proteins by determining altered electrophoretic binding properties.

3. 发明申请

US20080031873A1 Humanized monoclonal antibody 31.1 as an anticancer agent 审中-公开
标题翻译：人源化单克隆抗体31.1作为抗癌剂
公开(公告)号：US20080031873A1
公开(公告)日：2008-02-07
申请号：US11644048
申请日：2006-12-22
申请人： Jeffry Fasick , Nikos Panayotatos , Kwong Tsang
发明人： Jeffry Fasick , Nikos Panayotatos , Kwong Tsang
IPC分类号： A61K39/395 , A61P35/00 , C12N5/06 , C12P21/08
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/734
摘要： The present invention is directed to a CHO cell expression system for high level expression of a chimeric 31.1 monoclonal antibody specific for a human carcinoma-associated protein antigen. The present invention also provides a pharmaceutical composition comprising chimeric 31.1 monoclonal antibody derived from the CHO cells of the invention for use in immunotherapy or immunodiagnosis.
摘要翻译：本发明涉及用于高水平表达对人癌相关蛋白抗原特异性的嵌合31.1单克隆抗体的CHO细胞表达系统。本发明还提供一种药物组合物，其包含衍生自用于免疫治疗或免疫诊断的本发明的CHO细胞的嵌合31.1单克隆抗体。

4. 发明授权

US5872006A Family of MAP2 protein kinases 失效
公开(公告)号：US5872006A
公开(公告)日：1999-02-16
申请号：US461985
申请日：1995-06-05
申请人： Teri G. Boulton , Melanie H. Cobb , George D. Yancopoulos , Steven Nye , Nikos Panayotatos
发明人： Teri G. Boulton , Melanie H. Cobb , George D. Yancopoulos , Steven Nye , Nikos Panayotatos
IPC分类号： C12N1/21 , C12N9/12 , C12N15/09 , C12N15/54 , C12P21/08 , C12Q1/02 , C12Q1/48 , C12R1/19 , C12R1/91 , G01N33/50 , G01N33/573 , C12N15/63
CPC分类号： G01N33/5041 , C12N9/12 , C12Q1/485 , G01N33/5008 , G01N33/573 , G01N2333/9121 , G01N2500/00
摘要： The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease, peripheral neuropathies, and diabetes may be identified using the methods of the invention.

5. 发明授权

US5716803A Recombinant protein production with reduced expression of selectable markers 失效
标题翻译：重组蛋白生产与选择性标记的表达降低
公开(公告)号：US5716803A
公开(公告)日：1998-02-10
申请号：US6863
申请日：1993-01-21
申请人： Nikos Panayotatos
发明人： Nikos Panayotatos
IPC分类号： C07K14/525 , C12N1/21 , C12N15/67 , C12N15/70 , C12P21/00 , C07H21/04 , C12N15/63 , C12N15/65
CPC分类号： C07K14/525 , C12N15/67 , C12N15/70
摘要： The present invention relates to expression of recombinant proteins by use of a bacterial host expression vector which expresses a recombinant protein under the control of a first regulatory expression element, and expresses a selectable marker under the control of a second regulatory expression element, which second element is mutated such that expression of the selectable marker is at reduced levels relative to that directed by such an unmutated expression element. Such an expression vector in a suitable bacterial host (a) allows ease of purification of the recombinant protein of interest ("the recombinant protein") since less selectable marker is present to interfere with the purification of the recombinant protein, and (b) increases the amount of recombinant protein that is produced by the bacterial host cell. Furthermore, in an embodiment in which the selectable marker is an antibiotic resistance gene, expression according to the present invention ensures that only the minimal necessary levels of antibiotic will be used for selection during fermentation. The invention provides expression vectors, host-vector expression systems (comprising the expression vector in a bacterial host in which it can be expressed), and methods relating thereto.
摘要翻译：本发明涉及通过使用表达在第一调节表达元件控制下的重组蛋白的细菌宿主表达载体表达重组蛋白，并在第二调控表达元件的控制下表达选择性标记，该第二元件被突变，使得可选择标记的表达相对于由这种未突变的表达元件引导的表达降低。由于存在较少的选择性标记以干扰重组蛋白的纯化，所以在合适的细菌宿主（a）中的这种表达载体允许容易地纯化目标重组蛋白（“重组蛋白”），和（b）增加由细菌宿主细胞产生的重组蛋白的量。此外，在选择性标记是抗生素抗性基因的实施方案中，根据本发明的表达确保了在发酵期间仅将最低限度的必需水平的抗生素用于选择。本发明提供表达载体，宿主 - 载体表达系统（包括在其中可以表达的细菌宿主中的表达载体）以及与其相关的方法。

6. 发明申请

US20060269478A1 Use of protein occlusion for the selective delivery of small molecules to targets 审中-公开
公开(公告)号：US20060269478A1
公开(公告)日：2006-11-30
申请号：US11497684
申请日：2006-08-01
申请人： Nikos Panayotatos
发明人： Nikos Panayotatos
IPC分类号： A61K51/00 , A61K38/20 , A61K38/19
CPC分类号： A61K47/62
摘要： The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. The complexes of this invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the target-binding moiety portion of the complex. The present invention also relates to pharmaceutical compositions comprising the non-covalent complexes of this invention. The invention also relates to methods of delivering a pharmacological compound to a target in a patient. The present invention also relates to the use of the complexes of this invention for the separation of chemical entities from their chiral forms or contaminants.

7. 发明授权

US06410510B1 Administration modified ciliary neurotrophic factors 失效
标题翻译：行政修改睫状神经营养因子
公开(公告)号：US06410510B1
公开(公告)日：2002-06-25
申请号：US08645107
申请日：1996-05-13
申请人： Nikos Panayotatos , Keith D. Anderson , Stanley J. Wiegand , Ronald M. Lindsay
发明人： Nikos Panayotatos , Keith D. Anderson , Stanley J. Wiegand , Ronald M. Lindsay
IPC分类号： A61K3818
CPC分类号： C07K14/475 , A61K38/185
摘要： Modified ciliary neurotrophic factors and methods for their production and therapeutic use, especially in the treatment of Huntington's disease.
摘要翻译：改良的睫状神经营养因子及其生产和治疗用途的方法，特别是治疗亨廷顿病。

8. 发明授权

US5389529A Modified lam.beta. signal sequence and processes for producing recombinant neurotrophins 失效
标题翻译：改良的lamβ信号序列和重组神经营养蛋白的制备方法
公开(公告)号：US5389529A
公开(公告)日：1995-02-14
申请号：US796106
申请日：1991-11-21
申请人： Nikos Panayotatos , James P. Fandl
发明人： Nikos Panayotatos , James P. Fandl
IPC分类号： C07K14/245 , C07K14/475 , C12N15/70 , C12N15/11
CPC分类号： C07K14/245 , C07K14/475 , C12N15/70 , C07K2319/02
摘要： Signal sequences based on LamB have been constructed. These signal sequences facilitate both the synthesis and secretion of neurotrophins in E. coli.
摘要翻译：已经构建了基于LamB的信号序列。这些信号序列促进大肠杆菌中神经营养蛋白的合成和分泌。

9. 发明授权

US06406710B1 Protein occlusion for delivery of small molecules 失效
标题翻译：用于递送小分子的蛋白质闭塞
公开(公告)号：US06406710B1
公开(公告)日：2002-06-18
申请号：US09101860
申请日：1998-07-16
申请人： Nikos Panayotatos
发明人： Nikos Panayotatos
IPC分类号： A61F202
CPC分类号： A61K47/62
摘要： The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. The complexes of thus invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the target-binding moiety portion of the complex. The present invention also relates to pharmaceutical compositions comprising the non-covalent complexes of this invention. The invention also relates to methods of delivering a pharmacological compound to a target in a patient. The present invention also relates to the use of the complexes of this invention for the separation of chemical entities from their chiral forms or contaminants.
摘要翻译：本发明涉及（1）靶结合部分之间的复合物; （2）空腔形成部分; 和（3）待递送至靶的药物化合物，其中所述药理学化合物被掩埋在所述空腔形成部分的内部，但不共价结合于靶结合部分或空腔形成部分。本发明的复合物可以用于将药物化合物递送到细胞，组织，器官，病毒，微生物或其它表面，其特征在于结合复合物的靶结合部分部分的实体。本发明还涉及包含本发明的非共价复合物的药物组合物。本发明还涉及将药物化合物递送至患者中的靶标的方法。本发明还涉及本发明的复合物用于将化学实体与其手性形式或污染物分离的用途。

10. 发明授权

US06303358B1 ERK3 MAP2 protein kinase 失效
标题翻译： ERK3 MAP2蛋白激酶
公开(公告)号：US06303358B1
公开(公告)日：2001-10-16
申请号：US08888818
申请日：1997-07-07
申请人： Teri G. Boulton , Melanie H. Cobb , George D. Yancopoulos , Steven Nye , Nikos Panayotatos
发明人： Teri G. Boulton , Melanie H. Cobb , George D. Yancopoulos , Steven Nye , Nikos Panayotatos
IPC分类号： C12N912
CPC分类号： G01N33/5041 , C12N9/12 , C12Q1/485 , G01N33/5008 , G01N33/573 , G01N2333/9121 , G01N2500/00
摘要： The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease, peripheral neuropathies, and diabetes may be identified using the methods of the invention.
摘要翻译：本发明涉及磷酸化微管相关蛋白2（MAP2）的新鉴定的蛋白丝氨酸/苏氨酸激酶家族。它部分地基于在中枢神经系统中表达的称为细胞外信号调节激酶1,2和3（ERK1，ERK2，ERK3）的新型MAP2激酶的克隆和表征，以及鉴定另一种 ERK家族成员，ERK4，具有抗血清。本发明提供了代表MAP2激酶家族成员的重组核酸分子和蛋白质，还提供了包含重组MAP2激酶分子的微生物，转基因动物和细胞系。在本发明的另外的实施方案中，本发明提供了测定细胞因子活性的方法，包括但不限于神经生长因子活性，其中MAP2激酶的活化用作细胞因子活性的指标。这些方法在筛选化合物中以期存在所需的细胞因子活性可能是非常有用的。在具体实施方案中，可以使用本发明的方法鉴定可用于治疗阿尔茨海默氏病，周围神经病和糖尿病的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式